See the biotech and pharma companies that are growing the fastest and pay workers the most
- Insider compiled data on the fastest-growing
- We examined how much they're paying employees and executives.
- One company paid its median employee $701,000, while dozens of CEOs earned more than $18 million.
As the drug industry has grown, companies are competing to hire and retain the best people. That's true for every position from CEO all the way down to entry-level technicians.
To understand this battle for talent, Insider analyzed reports from more than 150 publicly traded pharma and biotech companies. We included companies with a market value of at least $1 billion. Our list includes companies that trade on two leading biotech indices - the XBI and the IBB - as well as a handful of multinational pharmaceutical companies.
We found dozens of companies that grew their workforce while other industries were conducting layoffs. Insider's reports showed that one biotech paid its median employee $701,000 last year. That company's CEO made $32,497,239 in 2020.
Read more: Employees at top biotech companies can get paid up to $701,000. Here's where workers made the most in 2020.
Here's what you should know about which companies are growing the fastest, and what they're paying.
Dozens of drug companies boosted their workforces by at least 50%
It's little surprise that biotechs developing COVID-19 vaccines and treatments, like IGM Biosciences, Moderna and Novavax, went on a hiring spree last year.
But growth wasn't limited to companies responding to the pandemic. Insider found 29 companies that grew their staff by at least 50% in 2020. Several of these companies said they plan to continue
Even startups are getting bigger. A series of new drug companies has emerged in the past two years that meld multiple smaller startups to either create a single new venture or a holding company with many subsidiaries. These startups are drawing large financing rounds and high valuations, creating companies that are larger in scale than a standard drug startup.
See the 29 fastest-growing biotech companies, which hired hundreds of new workers in 2020 and grew by at least 50%
A new wave of drug startups with big portfolios and precarious valuations has burst onto the scene. Welcome to the era of 'mega biotechs.'
To attract the best talent, drug companies are boosting salaries and throwing in equity
Experts have warned for years that the growth of drug companies is outpacing the number of scientists and researchers actually looking for jobs. Companies have to be competitive to grab the top talent.
Insider found the 23 best-paying biotechs, which all paid over $300,000 to their typical worker in 2020.
We also analyzed mandatory disclosure documents to reveal how much some of the largest biotech and pharmaceutical firms are paying workers. The analysis includes roles at companies like Eli Lilly, Johnson & Johnson, Merck, Moderna, Novartis, and Pfizer.
Read more: How much companies like Novartis, Pfizer, Johnson & Johnson, and Moderna pay scientists, engineers, doctors, and lawyers
Close to 30 drug company CEOs earned more than $18 million last year
High levels of
Most executives make the majority of their money from stock awards and bonuses. In 2020, that served them well. Novavax CEO Stanley Erck, for example, saw his
Read more: These are the 17 CEOs who made the most, led by Regeneron, Guardant Health and Royalty Pharma.
If you've read our articles on pay across the biotech and pharma industries, it's time to put your knowledge to the test. Take our 5-question quiz to see how well you know the pay trends shaping the drug industry.
- We asked ChatGPT who the greatest athlete of all time is and it did not go well for LeBron James
- A man kept the same pair of contact lenses in for 3 years, causing permanent astigmatism and buildup behind his eyelids. His doctor said he's not responsible enough to wear contacts.
- Clarence Thomas wrote a scathing, nearly 50-page dissent about why the Supreme Court should have gutted voting rights
- Railway jobs: 12,000 recruited under 'Rozgar Mela' initiative
- Realme 11 Pro 5G review – a mid-ranger with a premium design
- Realme 11 Pro+ 5G Review: Affordable luxury with some rough edges
- Learning curve: Edtechs at a crossroad
- Stock markets flat in early trade: HAL, Kotak Bank in focus